SLC5A2 and type 2 diabetes mellitus: In type 2 diabetes patients with established ischaemic heart disease and post coronary artery bypass grafting (CABG), SGLT-2 inhibitors ameliorate clinical outcomes and reduce inflammatory burden [15].